Bevacizumab is a biologic anti-cancer agent that prevents tumor growth by interfering with the formation of new blood vessels.
Now, a new study found that bevacizumab may have the potential to improve the efficacy of standard combination chemotherapy in ovarian cancer.
Ovarian cancer or cancer of the ovary is the fifth most common cancer in women and I reckon one of the deadliest.
Almost 70% of ovarian cancer patients fail to win against the disease despite chemotherapy.
According to Dr. Bram Goldstein, co-author of the study, whose findings are published in Vol. 17 Issue 4 of International Journal of Gynecological Cancer:
“The results from our …read more

The Lung Cancer Alliance (LCA) has applauded the USFDA on its recent approval of Avastin (bevacizumab) for the most common type of lung cancer.
Laurie Fenton, President of Lung Cancer Alliance in Washington, D.C. stated:
“Lung cancer is responsible for over one-third of all U.S. cancer deaths, killing more people than breast, prostate, colon, liver and kidney cancers combined each year.
Sadly, we have few arrows in our treatment quiver to address this lethal killer. That is why the ability to use Avastin as a treatment method, along with chemotherapy, is a significant development for the lung cancer community.”

Manufactured by Genentech, Inc. (NYSE: DNA), …read more